Navigation Links
Arvinas Secures $18.25 Million to Advance Clinical Programs Focused on Protein Degradation
Date:9/26/2013

NEW HAVEN, Conn., Sept. 26, 2013 /PRNewswire/ -- Arvinas Inc., a biotechnology company creating a new class of drugs based on protein degradation, today announced it has raised $15 million in Series A funds and $4.25 million in financial support, $1 million of which is in the form of equity, from the Connecticut Department of Economic and Community Development and Connecticut Innovations. Investors in the Series A round include co-leads Canaan Partners and 5AM Ventures along with Connecticut Innovations and Elm Street Ventures. The funds will support the development of the company's technology which has primary application in multiple oncology indications and potential in inflammatory, autoimmune and rare diseases.

Arvinas is built on the research of Craig Crews, PhD, Lewis B. Cullman Professor of Molecular, Cellular and Developmental Biology and professor of Chemistry and Pharmacology at Yale University. The new drugs being developed by Arvinas would induce a cell's own protein-degradation capabilities to bind to a particular protein and "label" it for degradation, thus removing a protein from the system entirely. This contrasts to a more traditional drug development approach that inhibits proteins.  However, only 25 percent of the body's 20,000 proteins can be inhibited. Proteins that cannot be inhibited can potentially be degraded using Arvinas' approach, radically expanding the number of disease-causing proteins that can become the targets of new drugs.

"Degrading proteins as opposed to inhibiting them has potential to open up areas of drug development that were previously closed because of the technical limitations of protein inhibition," said Tim Shannon, MD, CEO of Arvinas and Venture Partner at Canaan Partners. "The Arvinas technology platform represents an entirely new class of drugs bringing an innovative approach to treating disease."

"In
'/>"/>

SOURCE Arvinas Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Predilytics Secures Additional Funding and Expands Board of Directors
2. VisionCare Ophthalmic Technologies Secures Up To $15MM To Accelerate Growth Of Its Novel Treatment For Age-Related Macular Degeneration
3. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
4. Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
5. Endexx Secures Exclusive World Wide Rights for Medical Marijuana Dispensing Technology
6. BioMotiv Secures $46 Million in Funding
7. Stark Medical Secures GSA Schedule Contract, Looks to Supply VA
8. NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
9. Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
10. SecureState Identifies Top 5 Vulnerabilities Facing Hospitals and Medical Device Manufactures
11. Aviir Secures Third $10 Million Financing Tranche To Fund Expanded Sales Of New Heart Risk Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... and ATLANTA , August 28, ... US Food and Drug Administration (FDA) cleared the MagVita TMS ... adult patients who have failed to receive satisfactory improvement from ... non-invasive technique for stimulating neural tissue in the part of ... The procedure has been proven safe and effective and MagVenture ...
(Date:8/28/2015)... , Aug. 28, 2015 , ... Dr. Ra from Biostar , Published in ,Stem ... increase of lifespan through multiple IV administration of Adipose-derived ... and life expectancy found , Commercialization within 5 ... determined the possibility that adult mesenchymal stem cells (MSCs) ...
(Date:8/28/2015)... LONDRES, 28 de agosto de 2015   ... su participación en el  Congreso de la ESC ... más recientes y novedosas, entre ellas HeartModel A.I. ... las personas y la tecnología con los protocolos ... guiar los tratamientos y permitir atención en el ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... Asthma Medication Linked to Respiratory Improvement in NYC ... ... corticosteroids (ICS),antiinflammatory treatments often prescribed for asthma, may be beneficial,in preventing ... 2007, the 73rd annual international scientific assembly,of the American College of ...
... 24 Pharmasset, Inc.,(Nasdaq: VRUS ) has ... and,Drug Administration (FDA) for R7128 for the treatment ... a prodrug of PSI-6130, an oral cytidine,nucleoside analog ... Pharmasset,s collaboration with Roche. Pharmasset is currently,enrolling a ...
Cached Medicine Technology:Inhaled Steriods Used as Preventive Treatment Post 9/11 2Inhaled Steriods Used as Preventive Treatment Post 9/11 3R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection 2R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection 3R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection 4R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection 5
(Date:8/28/2015)... ... 28, 2015 , ... The Nashville Business Journal recently announced ... business. Mr. Troy Mizell, Chairman of the Board at MyGenetx, is one ... Veterans Awards will recognize Nashville military veterans who, through their professional and personal ...
(Date:8/28/2015)... CA (PRWEB) , ... August 28, 2015 , ... ... price on Zoom teeth whitening. For just $199, patients can currently receive a one ... traditional in-office teeth whitening procedures, but it includes a number of unique features that ...
(Date:8/28/2015)... ... August 28, 2015 , ... The newest therapy to ... available for general use any time soon, according to educational website Surviving Mesothelioma. ... that received orphan drug designation for mesothelioma last week from the FDA, will now ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... now consolidated as MDL 2545, Testosterone Replacement Therapy Products Liability Litigation, are in ... number of custodial files the PSC may receive for corporate employees involved in ...
(Date:8/28/2015)... ... 28, 2015 , ... An independent study recently conducted confirms ... of change to treatment recommendations and diagnosis. The 2015 return on investment (ROI) ... and analyzed WorldCare’s second opinion process. , The study reviewed cases across three ...
Breaking Medicine News(10 mins):Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4Health News:WorldCare International, Inc. Celebrates Findings of Independent ROI Study 2
... , ... poll, Supporting Iraq and Afghanistan Troops and Veterans, found two out of three Americans know ... and Afghanistan veterans and troops face. , ... Washington, DC (Vocus) May 10, 2010 -- A new public awareness poll, ...
... French . , Neurological research and clinical ... London and McGill University of Montreal entered an agreement ... field. Sir Keith O,Nions, Rector of Imperial, and Heather ... to sign the partnership documents, which will consolidate existing ...
... ... ... Clyburn will give the commencement address at the 135th Commencement ceremony for Meharry Medical College ... University in the Allen Arena. Doors open at 11:30 a.m., , , , ,Congressman Clyburn is ...
... show need for treatment even when pulmonary disease looks ... News) -- Worsening of chronic obstructive pulmonary disease (COPD) ... stroke, a new study finds. , British researchers looked ... in 426 patients and 633 ischemic strokes (blockage of ...
... help University of Central Florida researchers explore new ways ... and other neurological disorders. Stephen Lambert, an associate ... of UCF,s Hybrid Systems Laboratory, has received $428,000, the ... team will study the breakdown of myelin, a substance ...
... dyslexia often struggle with reading, writing, and spelling, despite ... other areas. New neurological research has found that these ... structural differences within an important information highway in the ... The findings are published in the June 2010 issue ...
Cached Medicine News:Health News:New Poll Finds Majority of Americans Are Unaware of Issues Facing Iraq/Afghanistan Veterans and Troops 2Health News:New Poll Finds Majority of Americans Are Unaware of Issues Facing Iraq/Afghanistan Veterans and Troops 3Health News:Trans-Atlantic agreement a boost to neuroscience research 2Health News:Congressman James E. Clyburn to Give Meharry Medical College Commencement Address 2Health News:Congressman James E. Clyburn to Give Meharry Medical College Commencement Address 3Health News:$1.9 million grant to help UCF find multiple sclerosis 'nerve-ana' 2Health News:Differences in language circuits in the brain linked to dyslexia 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: